PVLA

Price & events

Pipeline stages · 2 programs

Pipeline · 3 trials · 1 upcoming

Catalyst news & presentations · 12

• second half of 2027Guided 55%readoutPhase 2QTORIN rapamycin · Topline results from Phase 2 LOTU trialSEC 8-K
• second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)QTORIN rapamycin · NDA submission for QTORIN rapamycin for microcystic LMsSEC 8-K
• second half of 2026trial initiationsecondaryPhase 2QTORIN rapamycin · Initiate Phase 2 trial for clinically significant angiokeratomasSEC 8-K
• 2026-08-13earningsEarningsEarnings releaseyahoo
• first half of 2026filing acceptanceFiled (NDA/BLA)QTORIN pitavastatin · Plan to meet with FDA to discuss Phase 2 study design.SEC 8-K
• second quarter of 2026trial initiationsecondaryPhase 2QTORIN rapamycin · Initiation of Phase 2 trial for angiokeratomasSEC 8-K
• International Society for the Study of Vascular Anomalies World Congress 2026conferencedata presentationsecondaryPhase 3QTORIN rapamycin · Phase 3 SELVA study results presentedSEC 8-K
• first quarter of 2026readoutPhase 3QTORIN rapamycin · Phase 3 SELVA top-line results anticipated in Q1 2026SEC 8-K
• early 2026regulatory submissionFiled (NDA/BLA)QTORIN rapamycin · Planned discussions with FDA for Breakthrough Therapy Designation and Phase 3 study design.SEC 8-K
• fourth quarter of 2025readoutPhase 2QTORIN rapamycin · Phase 2 TOIVA top-line results anticipated in Q4 2025SEC 8-K
• June 2025enrollment completesecondaryPhase 3QTORIN rapamycin · SELVA trial enrollment expected to close in June 2025SEC 8-K
• 2024-10-03fda agreementQTORIN 3.9% rapamycin gel · FDA Office of Orphan Products Development awarded up to $2.6M grant over four years for Phase 3 SELVA study in microcystic lymphatic malformationsSEC 8-K